# Efficacy and Safety of TD-1473 in Crohn's Disease

> **NCT03635112** · PHASE2 · TERMINATED · sponsor: **Theravance Biopharma** · enrollment: 167 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** TD-1473

## Key facts

- **NCT ID:** NCT03635112
- **Lead sponsor:** Theravance Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-19
- **Primary completion:** 2021-12-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 167 (ACTUAL)
- **Why stopped:** The study was terminated by the sponsor on 16 November 2021 after a planned review by the Independent Data Monitoring Committee.
- **Last updated:** 2023-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03635112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03635112, "Efficacy and Safety of TD-1473 in Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03635112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*